Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Jan 1;28(1):121-127.
doi: 10.1093/annonc/mdw444.

A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas

M Agulnik  1 , R L B Costa  1 , M Milhem  2 , A W Rademaker  1 , B C Prunder  3 , D Daniels  3 , B T Rhodes  3 , C Humphreys  1 , S Abbinanti  1 , L Nye  1 , R Cehic  1 , A Polish  1 , C Vintilescu  1 , T McFarland  4 , K Skubitz  5 , S Robinson  6 , S Okuno  6 , B A Van Tine  3
Affiliations
Clinical Trial

A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas

M Agulnik et al. Ann Oncol. .

Abstract

Background: Soft tissue sarcomas (STSs) overexpress vascular endothelial growth factors (VEGF) and VEGF-receptors (VEGFR) activation have been associated with tumor aggressiveness. Tivozanib is a potent small molecule tyrosine kinase inhibitor against VEGFR1-3, with activity against PDGFRα/β and cKIT. The primary endpoint of this study was progression free survival (PFS) rate at 16 weeks. Secondary end points were overall survival (OS), response rate, safety and correlative studies.

Patients and methods: A Simon two-stage phase II trial was performed using tivozanib given orally at 1.5 mg daily, 3 week on 1 week off on a 28 day cycle until disease progression or intolerable toxicity.

Results: Fifty-eight patients were enrolled and treated with tivozanib. Leiomyosarcoma was the most common STS histological type in our cohort (47%) and 27 patients (46%) had received at least 3 lines of therapy prior to study entry. Up to 24 patients (41%) had prior VEGF targeted therapies. Partial response and stable disease were observed in 2 (3.6%) and 30 (54.5%) patients. The 16 week PFS rate was 36.4% [95% confidence interval (CI) 23.7-49.1] and a median PFS of 3.5 months (95% CI 1.8-3). Median OS observed was 12.2 months (95% CI 8.1-16.8). The most frequent all grade toxicities were fatigue (48.3%), hypertension (43.1%), nausea (31%) and diarrhea (27.6%). The most common grade three toxicity was hypertension (22.4%). Correlative studies demonstrate no correlation between the expression of VEGFR 1, 2 or 3, PDGFRα/β or FGF, and activity of tivozanib.

Conclusion: Tivozanib was well tolerated and showed antitumor activity with a promising median PFS and PFS rate at 4 months in a heavily pretreated population of metastatic STSs. Our results support further studies to assess the clinical efficacy of tivozanib in STS.

Clinical trial number: NCT01782313.

Keywords: phase II; sarcoma; tivozanib; tyrosine kinase inhibitor.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan–Meier curve of progression free survival (—) and overall survival (__) for all evaluable patients on study (n = 58). Median progression free survival was 3.5 months, (95% CI 1.8–3), and the median OS was 12.2 months, (95% CI 8.1–16.8).
Figure 2.
Figure 2.
Kalan-Meier curves demonstrating no correlation between expression of (A) VEGFR1 (B) VEGFR2 (C) VEGFR3 (D) PDGFRa (E) PDGFRb with days on trial. The changes in circulating expression between day 30 minus day 1 of (F) VEGF (G) PDGFRa (H) PDGFRb (E) FGF2 did not correlate with time on trial.
See this image and copyright information in PMC

Comment in

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5–29. - PubMed
    1. Santoro A, Tursz T, Mouridsen H. et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol 1995; 13: 1537–1545. - PubMed
    1. Lorigan P, Verweij J, Papai Z. et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European organisation for research and treatment of cancer soft tissue and bone sarcoma group study. J Clin Oncol 2007; 25: 3144–3150. - PubMed
    1. Ryan CW Schoffski P Merimsky Oet al. PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. J Clin Oncol. 2016 Sep 12; pii: JCO676684. - PubMed
    1. Tap WD, Jones RL, Van Tine BA. et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016; 388(10043): 488–97. doi: 10.1016/S0140-6736(16)30587-6. - PMC - PubMed

Publication types

MeSH terms

Associated data